Mark Hancock sold 142,163 shares of $PACS Group, Inc. ($PACS) on July 6, 2026, at an average price of approximately $45.33 per share, bringing the total to roughly $6.4 million. The open-market sale was filed with the SEC the same day. After the transaction, Hancock held approximately 53.9 million shares.
The July 6 sale was the largest in a string of open-market disposals over the prior two weeks. On July 2, he sold 12,825 shares at approximately $45.01 per share for about $577,000; a day earlier, on July 1, he sold 6,080 shares at approximately $45.02 per share for roughly $274,000. Both transactions appeared in the same July 6 filing. Earlier, on June 25, Hancock sold 138,069 shares at around $40.33 per share, a transaction valued at approximately $5.6 million. The following day he sold 61,731 shares at around $40.50 per share, adding roughly $2.5 million, plus a small additional sale of 200 shares at $41.01 also recorded on June 26.
Across all six transactions spanning June 25 through July 6, Hancock's disclosed sales total approximately 361,068 shares with a combined value of around $15.4 million. His title on the earlier June filings listed him as Co-Founder and Executive Vice Chair; the July filing identifies him as Director.
Hancock is not the only $PACS insider to have sold shares in recent months. John Todd Mitchell, the company's Chief Legal Officer and Secretary, recorded sales totaling approximately $3.0 million across four transactions in May 2026, with shares priced between roughly $37 and $39. COO Joshua Jergensen sold 36,335 shares in March 2026 for approximately $1.2 million at around $34.28 per share. The one purchase in the database over the same window was a roughly $500,000 open-market buy by director Evelyn S. Dilsaver in November 2025, recorded at approximately $29.90 per share.
$PACS Group operates in the Health Care sector. Hancock's most recent transactions were executed in the mid-$40s range, compared to the mid-to-upper $30s that characterized the Mitchell and Jergensen sales in the first half of 2026 and the high-$20s range of Dilsaver's November purchase.